High DHEA-S In Women: Causes, Labs, And What To Do

High DHEA-S in women is one of the most common lab findings in an androgen workup, and the most common cause isn't a tumor. In a consecutive series of 1,205 women referred for androgen excess, 80% of those with severely elevated DHEA-S before menopause had polycystic ovary syndrome (PCOS), not an adrenal malignancy (Elhassan et al., 2018). That statistic rarely appears on the first page of search results for this topic. Understanding what DHEA-S is, why it rises, and which follow-up labs matter can prevent both unnecessary panic and missed diagnoses. Diagnostic lab testing makes it possible to check DHEA-S without a referral, but reading the result correctly requires age-specific ranges, a full androgen panel, and clinical context.

DHEA-S (dehydroepiandrosterone sulfate) is a sulfated steroid hormone produced in the adrenal zona reticularis. It serves as a precursor to both testosterone and estrogen. Because the adrenal glands are its near-exclusive source, a high DHEA-S result signals adrenal overproduction rather than ovarian androgen excess (Elhassan et al., 2025).

What Is DHEA-S?

DHEA-S is the sulfated storage form of dehydroepiandrosterone (DHEA). It circulates at concentrations 100 to 500 times higher than unconjugated DHEA, and its half-life is roughly 10-20 hours compared to about 30 minutes for free DHEA. That stability makes DHEA-S the preferred lab measurement for adrenal androgen output.

DHEA and DHEA-S are not interchangeable tests. Unconjugated DHEA is pulsatile and labile. Ordering "DHEA" on a wellness panel and interpreting it as DHEA-S is a common error in direct-to-consumer testing. Labcorp lists them under separate CPT codes (82626 vs. 82627). When the clinical question is adrenal androgen excess, DHEA-S is the correct test.

DHEA-S peaks in the early-to-mid 20s, then declines with age. A value that sits inside the reference range for a 22-year-old may be flagged as high for a 50-year-old. The Society for Endocrinology (SfE) 2025 guideline on androgen excess in women states that results must be interpreted against age-specific or pre- and postmenopausal ranges and, where possible, measured by a validated LC-MS/MS assay (Elhassan et al., 2025).

One practical problem: reference ranges differ across labs. The upper limit for a woman in her early 20s can vary by a clinically meaningful margin between 2 major platforms running different assays. The same woman can be "high" at one lab and "normal" at another. Clinicians who work with individual biomarker testing read results against the specific lab's age-matched range, not a single universal number. A provider familiar with the assay used is the right person to interpret the result.

Symptoms of High DHEA-S in Women

Elevated DHEA-S in women can contribute to symptoms of androgen excess because peripheral tissues convert DHEA-S toward testosterone and dihydrotestosterone (DHT). The 2018 Endocrine Society clinical practice guideline on hirsutism describes these clinical signs in women with biochemically confirmed androgen excess (Martin et al., 2018):

• Hirsutism (excess terminal hair on the face, chest, or abdomen, scored with a modified Ferriman-Gallwey scale)

• Acne that persists beyond adolescence or worsens in adulthood

• Androgenic alopecia (thinning at the crown and frontal hairline)

• Irregular or absent menstrual cycles

• Deepening of the voice (a sign of frank virilization, which is rare in PCOS and raises concern for a tumor or congenital adrenal hyperplasia)

• Clitoromegaly (also a virilization sign, not a PCOS feature)

These signs don't confirm a specific condition on their own, but they may warrant testing for androgen excess, including a DHEA-S draw. Not every woman with high DHEA-S has symptoms. Isolated biochemical elevation without clinical signs still warrants follow-up labs to rule out rarer causes, but the pace and severity of symptoms guide how urgently to investigate.

Rapid onset over weeks to a few months, or any frank virilization, is a clinical red flag. The Endocrine Society and the SfE 2025 guideline both list rapid progression and virilization as indications for urgent imaging and specialist referral.

Why Would DHEA-S Be High?

The causes of high DHEA-S in women range from very common (PCOS) to very rare (adrenal carcinoma). A common misconception in online health content is the claim that a specific DHEA-S cutoff automatically indicates an adrenal tumor. Elhassan et al. (2018) showed that in premenopausal women, severe DHEA-S excess was still PCOS in 80% of cases. The SfE 2025 guideline declines to set a single numeric cutoff for imaging because assay variability makes one-size-fits-all thresholds unreliable. The context around the number, not the number alone, determines the next step.

Polycystic Ovary Syndrome

PCOS is the most common hormonal disorder in women of reproductive age, affecting an estimated 8-13% of premenopausal women (Elhassan et al., 2025). It's also the most common cause of elevated DHEA-S in this group. The 2023 International Evidence-based PCOS Guideline requires 2 of 3 criteria for diagnosis: clinical or biochemical androgen excess, ovulatory dysfunction, and polycystic ovarian morphology (or AMH in adults as an alternative to ultrasound) (Teede et al., 2023). Other causes must be excluded first.

Isolated high DHEA-S with normal testosterone and normal androstenedione was the most frequent abnormal androgen pattern in premenopausal women in the Elhassan 2018 series, showing up in 37.3% of those with at least 1 abnormal androgen level (Elhassan et al., 2018). This finding matters. Normal testosterone doesn't rule out PCOS when DHEA-S is elevated.

PCOS carries long-term metabolic associations including insulin resistance, type 2 diabetes, metabolic-associated fatty liver disease, and cardiovascular disease. When a PCOS diagnosis is confirmed, guidelines recommend metabolic screening (A1c, lipids, blood pressure) alongside the androgen panel. Clients who order a lab bundle that covers both hormonal and metabolic markers get a more complete picture than a standalone DHEA-S draw.

Nonclassic Congenital Adrenal Hyperplasia

Nonclassic congenital adrenal hyperplasia (NCCAH) affects about 4.2% of women with androgen excess worldwide, with higher rates in certain ethnic groups (Ashkenazi Jewish, Hispanic, Mediterranean) (Martin et al., 2018). It results from a partial deficiency of 21-hydroxylase, the same enzyme affected in classic CAH but with less severe disruption.

NCCAH can mimic PCOS almost exactly. Both cause hirsutism, acne, irregular cycles, and elevated androgens. The distinguishing lab is not DHEA-S. The Endocrine Society 2018 CAH guideline recommends screening with an early-morning 17-hydroxyprogesterone (17-OHP), ideally drawn in the follicular phase or on a random day if cycles are infrequent. An elevated basal 17-OHP may prompt cosyntropin stimulation testing. A provider interprets the stimulated result against published guideline thresholds to confirm or rule out the condition (Speiser et al., 2018).

Missing NCCAH can change the treatment plan and may affect reproductive planning, since genetic counseling may be warranted.

Adrenal Tumors

Androgen-secreting adrenal tumors are rare, found in about 0.2% of women evaluated for androgen excess (Martin et al., 2018). When they do occur, more than half are malignant. The clinical clue is pace. Adrenal carcinoma typically produces rapid virilization over weeks to months, not the slow progression seen in PCOS.

Menopausal status changes the interpretation. In the Elhassan 2018 referral series, severely elevated DHEA-S in postmenopausal women was consistently associated with adrenocortical carcinoma (ACC). That same level in a premenopausal woman in her 20s was usually PCOS. Cussen et al. (2022) proposed separate imaging thresholds for premenopausal and postmenopausal women, with a much lower trigger after menopause. The SfE 2025 guideline chose not to endorse a single imaging threshold, citing assay-to-assay variability.

Table: Androgen patterns by menopausal status, adapted from Elhassan et al., 2018. No single value confirms a condition on its own. Clinical pace, virilization, and the full panel guide next steps.

Can Stress Raise DHEA-S?

Acute stress raises DHEA-S transiently. DHEA-S levels tend to peak toward the end of an acute stress event and return to baseline afterward. This response is more pronounced in younger women and in women with higher body mass.

Chronic stress is different. Prolonged cortisol overproduction can suppress DHEA-S over time, not raise it. A standalone high DHEA-S result is not a stress marker without a broader adrenal panel. Clients who want to evaluate adrenal function alongside DHEA-S can include cortisol in their lab order. Interpreting either hormone in isolation gives an incomplete picture.

Medications and Supplements

Several medications can raise measured DHEA-S. These include certain calcium channel blockers (amlodipine, diltiazem, nifedipine), alprazolam, methylphenidate, anastrozole, and danazol. Nicotine also raises DHEA-S levels.

The most common overlooked cause of high DHEA-S in direct-to-consumer lab results is oral DHEA supplementation. DHEA capsules are sold as dietary supplements in the U.S. under DSHEA. They are not FDA-approved drugs for systemic use. Taking oral DHEA raises measured DHEA-S directly, and the label dose may not match the actual content. This creates a closed loop: a client takes DHEA, the lab flags a high result, and the follow-up workup chases an abnormality that the supplement itself produced. A recent Marek Diagnostics article on how medications affect results covers supplement disclosure before a blood draw in more detail.

DHEA is also prohibited by the World Anti-Doping Agency (WADA) and the NCAA. Women who compete in tested sports should confirm whether any supplement they take contains DHEA.